Please login to the form below

Not currently logged in
Email:
Password:

Alnylam

This page shows the latest Alnylam news and features for those working in and with pharma, biotech and healthcare.

Biotech leaders jump into US free speech debate

Biotech leaders jump into US free speech debate

Biotech leaders jump into US free speech debate. Senior officials from Alnylam, Decibel Therapeutics and more sign the letter in defence of free speech. ... Alnylam chief executive John Maraganore, Decibel Therapeutics’CEO Steve Holtzman, Acorda CEO

Latest news

More from news
Approximately 10 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Brexit: the facts (and the alternative facts) Brexit: the facts (and the alternative facts)

    Two post-referendum announcements have boosted the UK Government. GSK announced a £275 million investment in its UK manufacturing sites and Alnylam, a US biotech worth $6.5bn, said it would

  • Managing value: Why early asset development and commercialisation are important Managing value: Why early asset development and commercialisation are important

    For example, Alnylam Pharmaceuticals, with its lead product in phase III, has a market capitalisation of $7.4bn, despite having no marketed products; or Achillion Pharmaceuticals with a market capitalisation of

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    Alnylam/ Genzyme. Extended agreement. Additional markets for patisiran and 3 pipeline products with option to all rare disease products. ... 300. Merck/Alnylam. Divestment. Sale of Merck's RNAi therapeutics unit Sirna. 290.

  • Pharma deals during January 2014 Pharma deals during January 2014

    One of the key players was Alnylam which had double news to impart last month. ... The other deal announced by Alnylam was the expansion of its deal with Sanofi (Genzyme unit_ to develop RNAi therapeutics in rare diseases.

  • Pharma deals during November 2012 Pharma deals during November 2012

    100. Tekmira / Alnylam. Patent settlement. Lipid nanoparticle (LNP) technology. 75.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Editas Medicine adds to board of directors Editas Medicine adds to board of directors

    Editas Medicine adds to board of directors. Alnylam Pharmaceuticals’ Dr Akshay Vaishnaw joins. ... He has extensive clinical development experience, a passion for scientific excellence, and achieved significant accomplishments as part of the leadership

  • VC firm expands team, appoints Genzyme and Lilly veterans VC firm expands team, appoints Genzyme and Lilly veterans

    The firm, which focuses on building healthcare companies, has appointed former executives from Genzyme, Lilly, ImClone and Alnylam to help it translate scientific innovation into new companies. ... Also joining Third Rock as venture partners are Daniel

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics